SAVA Cassava Sciences, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

SAVA [NASD]

Cassava Sciences, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.23	Insider Own	7.10%	Shs Outstand	24.48M	Perf Week	-0.94%
Market Cap	51.57M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	55.30%	Shs Float	22.19M	Perf Month	-72.36%
Income	-4.40M	PEG	-	EPS next Q	-0.06	Inst Own	25.20%	Short Float	11.17%	Perf Quarter	-67.39%
Sales	-	P/S	-	EPS this Y	56.70%	Inst Trans	29.80%	Short Ratio	1.16	Perf Half Y	46.53%
Book/sh	1.01	P/B	2.09	EPS next Y	-769.20%	ROA	-20.40%	Target Price	-	Perf Year	91.82%
Cash/sh	1.05	P/C	2.01	EPS next 5Y	-	ROE	-21.50%	52W Range	1.03 - 10.95	Perf YTD	-59.42%
Dividend	-	P/FCF	-	EPS past 5Y	32.60%	ROI	-	52W High	-80.73%	Beta	3.02
Dividend %	-	Quick Ratio	22.60	Sales past 5Y	-	Gross Margin	-	52W Low	104.85%	ATR	0.74
Employees	9	Current Ratio	22.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.88	Volatility	5.79% 14.05%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	40.70%	Profit Margin	-	Rel Volume	0.50	Prev Close	2.14
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.14M	Price	2.11
Recom	2.00	SMA20	-59.01%	SMA50	-59.84%	SMA200	-46.35%	Volume	1,079,665	Change	-1.40%

May-18-20

Downgrade

H.C. Wainwright

Buy → Neutral

May-15-20

Downgrade

Maxim Group

Buy → Hold

Jan-10-20

Reiterated

Maxim Group

Buy

$3 → $12

May-19-20 07:57PM	Cassava Sciences (SAVA): Lets Shed Some Light on That Crash TipRanks
09:46AM	Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% Higher Zacks
May-15-20 02:05PM	Cassava Sciences Alzheimer's Drug Candidate Misses Trial Endpoint TheStreet.com -73.86%
11:31AM	Cassava stock falls on failed Alzheimer's study MarketWatch
08:15AM	Top-line Results from a Phase 2b Study of PTI-125 in Alzheimers Disease Does Not Meet Primary Endpoint GlobeNewswire
May-06-20 08:48AM	Add Value to Your Portfolio With 5 High Earnings Yield Picks Zacks
08:15AM	Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
May-03-20 07:30PM	One Biotech Stock For 2020 Oilprice.com
Apr-24-20 10:03AM	Company News for Apr 24, 2020 Zacks
Apr-23-20 08:15AM	Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health GlobeNewswire +31.95%
Apr-13-20 01:25PM	We're Excited To See How Cassava Sciences (NASDAQ:SAVA) Uses Its Cash Hoard To Grow Simply Wall St. +14.35%
Mar-26-20 08:15AM	Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020 GlobeNewswire
Mar-25-20 08:15AM	Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimers Disease GlobeNewswire
Mar-19-20 08:15AM	Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline GlobeNewswire +11.32%
Mar-02-20 11:04AM	What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings? Zacks +15.33%
Feb-11-20 08:15AM	Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimers Disease (JPAD) GlobeNewswire
Jan-28-20 08:15AM	Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimers Disease GlobeNewswire +21.12%
Jan-10-20 09:33AM	The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences Zacks
Jan-09-20 06:19AM	Buy Multibagger Stocks as Odds of a Rally Are High in 2020 Zacks -7.79%
Jan-08-20 11:23AM	Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics Zacks +11.69%
Jan-07-20 09:03AM	5 Stocks With Recent Price Strength for Spectacular Returns Zacks -10.78%
Jan-06-20 05:05AM	Are Insiders Buying Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? Simply Wall St. -10.57%
Jan-03-20 10:36AM	Company News For Jan 3, 2020 Zacks +34.03%
08:22AM	The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma Zacks
Jan-02-20 10:19AM	5 Stocks to Soar in 2020 After Solid Gains in 2019 Zacks +38.46%
08:38AM	Cassava's stock rises 33% MarketWatch
Dec-27-19 02:19PM	Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks +29.28%
Dec-10-19 07:42AM	Top Ranked Momentum Stocks to Buy for December 10th Zacks
Dec-06-19 03:08PM	Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch
10:58AM	Cassava stock is up on Alzheimer's data MarketWatch
07:39AM	The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
Dec-05-19 09:00PM	Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimers Disease at CTAD 2019 GlobeNewswire
Dec-04-19 09:26AM	Top Ranked Momentum Stocks to Buy for December 4th Zacks
Dec-01-19 09:30AM	The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-05-19 12:06PM	We Think Cassava Sciences (NASDAQ:SAVA) Can Easily Afford To Drive Business Growth Simply Wall St.
Oct-29-19 08:15AM	Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results GlobeNewswire +5.51%
Oct-24-19 08:30AM	Cassava Sciences Clinical Results in Alzheimers Selected as Late-Breaking News at CTAD 2019 GlobeNewswire +5.99%
Sep-20-19 10:02AM	6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day Zacks -8.46%
Sep-16-19 08:30AM	Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimers Patients GlobeNewswire
Sep-09-19 02:42PM	Failure of Alzheimers Disease Study Creates a New Penny Stock Bloomberg -12.86%
12:17PM	A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
07:30AM	Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimers Patients GlobeNewswire
Sep-06-19 11:50AM	How Cassava Sciences, Inc. (NASDAQ:SAVA) Can Impact Your Portfolio Volatility Simply Wall St. +10.24%
Sep-03-19 08:30AM	Cassava Sciences to Present at H.C. Wainwrights 21st Annual Global Investment Conference GlobeNewswire +17.86%
Aug-12-19 08:30AM	Cassava Sciences Announces Second Quarter 2019 Financial Results GlobeNewswire -6.77%
Jul-08-19 02:51PM	What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? Simply Wall St.
Jun-18-19 08:30AM	Cassava Sciences to Present at Maxim Groups Conference on Alzheimers Disease GlobeNewswire
May-28-19 08:29AM	Cassava Sciences Announces New Website Launch GlobeNewswire
May-23-19 04:35PM	Weekly CFO Buys Highlight GuruFocus.com
May-16-19 10:36AM	Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings Simply Wall St.
Apr-29-19 08:30AM	Cassava Sciences Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-15-19 08:30AM	Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimers Disease GlobeNewswire

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBIER REMI	President and CEO	Dec 31	Buy	5.53	100,000	553,000	1,068,855	Dec 31 04:10 PM
BARBIER REMI	President and CEO	Dec 26	Buy	4.15	10,000	41,500	968,855	Dec 26 04:03 PM
ROBERTSON SANFORD	Director	Dec 20	Buy	2.20	423,788	932,334	662,623	Dec 20 04:11 PM
Schoen Eric	Chief Financial Officer	Dec 19	Buy	1.88	5,300	9,964	15,300	Dec 19 06:06 PM
ROBERTSON SANFORD	Director	Dec 19	Buy	1.86	76,212	141,754	238,835	Dec 19 06:04 PM
BARBIER REMI	President and CEO	Dec 18	Buy	1.65	2,599	4,288	2,599	Dec 20 04:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience